Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin′s lymphoma

Pervez, Shahid; Nasir, Muhammd I; Moatter, Tariq; Ahsan, Adeeb; Haq, Amna; Siddiqui, Tariq

doi:10.4103/0973-1482.59901

Cited by 5 publications

(7 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pervez et al reported positive Bcl-2 protein expression in 75 of 117 (64.1%) patients in their study on 117 patients with DLBCL. However, there was no significant difference in OS between patients with negative or weakly positive Bcl-2 and high Bcl-2 expressions [22]. Similarly, in the present study, we did not show any difference in the outcome of patients with Bcl-2-positive or Bcl-2-negative DLBCL.…”

Section: Discussionsupporting

confidence: 55%

“…It is involved in the regulation of cell survival by interaction with G-S phase transition within the cell cycle and by induction of apoptotic cell death [17,18]. The incidence of p53 expression in DLBCL varies between 5.0% and 71.0% [5,6,7,10,14,19,20,21,22]. In the present study, p53 expression was identified in 62.9% of all cases and high p53 expression was identified in 10 patients (28.6%).…”

Section: Discussionmentioning

confidence: 99%

“…Zhang et al reported an inverse relationship between p53 expression and disease-free survival time [7]. Pervez et al observed p53 nuclear expression in 52.13% of cases; it was concluded that p53 overexpression was associated with decreased OS (22). …”

Section: Discussionmentioning

confidence: 99%

“…The effects of Bcl-2 on clinical course have been widely studied with quite a few lymphoma types previously [5,6,7,10,13,19,20,26,27]. The incidence of Bcl-2 expression in DLBCL varies between 24.0% and 77.0% [5,6,7,10,13,20,22,24,26,27,28]. In the present study, 13 (37.1%) cases out of 35 showed Bcl-2 protein expression in tumor cells and 9 (25.7%) cases out of 35 exhibited high levels (>50.0% of tumor cells staining) of Bcl-2 protein expression.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic Significance of Bcl-2 and p53 Protein Expressions and Ki67 Proliferative Index in Diffuse Large B-cell Lymphoma

Kucukzeybek¹,

Bener²,

Çallı³

et al. 2013

Tjh

View full text Add to dashboard Cite

Objective: Diffuse large B-cell lymphoma (DLBCL) is a high-grade neoplasm that has heterogeneous properties in clinical, morphological, and immunophenotypic aspects. In the present study the effects of p53, Bcl-2, and Ki67 on prognosis and their relationships with clinical parameters were examined.   Materials and Methods: Thirty-five patients who had been diagnosed with nodally located DLBCL at İzmir Atatürk Training and Research Hospital between January 1999 and June 2006 were included in the study. The Ann Arbor classification system was used to determine the stage of the patients. The patients were evaluated according to age, sex, stage, B symptoms, extranodal involvement, and lactate dehydrogenase (LDH) level as well as immunohistochemically. P53 protein and Bcl-2 oncoprotein expressions and Ki67 proliferation index were assessed immunohistochemically. Results: High Bcl-2 expression was found in 9 patients (25.7%), high p53 expression was found in 10 patients (28.6%), and high Ki67 was observed in 23 patients (65.7%). There was no significant correlation between p53 expression, Bcl-2 expression, or Ki67 proliferation index and age, sex, stage, B symptoms, extranodal involvement, LDH level, and overall survival (p>0.05). We did not find a relationship among p53 expression, Bcl-2 expression, Ki67 proliferation index, and prognosis (p>0.05). There was no significant relationship between overall survival and age, sex, stage, B symptoms, extranodal involvement, or LDH level (p>0.05). Our results revealed that Bcl-2 and p53 protein expressions and Ki67 proliferation index have no effect on overall survival of patients with DLBCL.Conclusion: The prognostic importance of p53 and Bcl-2 protein expressions and Ki67 proliferation index in DLBCL, which has biological and clinical heterogeneity, can be understood in a large series of studies that have subclasses and immunohistochemical markers with optimal cut-off values.

show abstract

Section: Discussionsupporting

confidence: 55%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic Significance of Bcl-2 and p53 Protein Expressions and Ki67 Proliferative Index in Diffuse Large B-cell Lymphoma

Kucukzeybek¹,

Bener²,

Çallı³

et al. 2013

Tjh

View full text Add to dashboard Cite

show abstract

“…The incidence of and mortality from lymphoma are higher in the Uighur ethnic group of Xinjiang than in people from eastern coastal regions. With a male to female ratio of 2.3:1, lymphoma has two peaks of incidence at younger than 10 years and 31-50 years in the population (Pervez et al, 2009). Malignant lymphoma has highly homogenous features but has various subtypes and classifications.…”

Section: Introductionmentioning

confidence: 99%

Genetic characteristics of non-Hodgkin lymphoma in ethnic Uighur people, and their clinical significance

Xu¹,

Zou²,

Wang³

et al. 2016

Genet. Mol. Res.

View full text Add to dashboard Cite

The incidence of non-Hodgkin lymphoma (NHL) in China is increasing and is attracting attention as a topic of research. The percentage of NHL cases in ethnic Uighur people is also gradually increasing. We therefore recruited Uighur people with NHL to investigate the correlation between genetic alternations and clinical/pathological features in an attempt to determine their clinical significance. A total of 60 NHL patients were recruited from our hospital for a microscopic examination of their tumor cell morphology. Further analysis of chromosome karyotypes revealed the relationship between genetic alternations and clinical/pathological features. Microscopic examination revealed increased numbers of tumor cells with altered morphology. The recruited patients all exhibited abnormal karyotypes. Chromosomal breakages were detected at 14q32, 18q21, 6q21-25, +3, +, +18, and short tandem repeat 17 (str17) in 18.3, 25, 25, 18.3, 15, and 21.7% of patients, respectively. Karyotype change was not related to age, gender, performance status score, or pathological type (P > 0.05), but was correlated with clinical stage, average lactate dehydrogenase (LDH) level, extra-lymphatic metastasis, median survival time, and efficacy of radio- or chemotherapy (P < 0.05). Independent risk factors for genetic change in Uighur NHL patients included clinical stage, average LDH level, extra-lymphatic metastasis, median survival time, and efficacy of radio- or chemotherapy (P < 0.05). Uighur NHL patients exhibited genetic changes including t(14:18), 6q21-25, +3, +7, +18, and str17. Clinical stage, average LDH level, extra-lymphatic metastasis, median survival time, and efficacy of radio- or chemotherapy were all independent risk factors for NHL.

show abstract

Protein–protein interaction networks and different clustering analysis in Burkitt’s lymphoma

et al. 2017

View full text Add to dashboard Cite

show abstract

Characterization of genetic lesions in apoptosis-regulating and proliferation control genes in diffuse large B-cell non-Hodgkin′s lymphoma

Abstract: Our data suggest that simple p53 protein expression by IHC at the time of diagnosis may help to identify high-risk patients, who may benefit with more aggressive and newer treatments in addition to standard CHOP.

Cited by 5 publications

References 27 publications

Prognostic Significance of Bcl-2 and p53 Protein Expressions and Ki67 Proliferative Index in Diffuse Large B-cell Lymphoma

Prognostic Significance of Bcl-2 and p53 Protein Expressions and Ki67 Proliferative Index in Diffuse Large B-cell Lymphoma

Genetic characteristics of non-Hodgkin lymphoma in ethnic Uighur people, and their clinical significance

Protein–protein interaction networks and different clustering analysis in Burkitt’s lymphoma

Contact Info

Product

Resources

About